Skip to main content

Table 4 Best overall response in the as-treated population

From: Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Response, n (%) Q3W (mg/kg) Q2W (mg/kg) QW x 2 (mg/kg) QW x 4 (mg/kg) Total
Cohort 1
0.1
n = 5 (%)
Cohort 2
0.5
n = 5 (%)
Cohort 3
2.5
n = 3 (%)
Cohort 4
10
n = 6 (%)
Cohort 5
20
n = 9 (%)
Cohort 6
10
n = 4 (%)
Cohort 7
20
n = 18 (%)
Cohort 8
20
n = 3 (%)
Cohort 9
20
n = 5 (%)
N = 58 (%)
Objective response 0 0 0 1 (17) 3 (33) 1 (25) 3 (17) 0 0 8 (14)
 CR 0 0 0 0 1 (11)b 0 0 0 0 1 (2)
 PR 0 0 0 1 (17)c 2 (22)d 1 (25)e 3 (17)b 0 0 7 (12)
 SD 0 0 1 (33) 2 (33) 2 (22) 1 (25) 6 (33) 2 (67) 4 (80) 18 (31)
 PD 3 (60) 3 (60) 1 (33) 1 (17) 3 (33) 2 (50) 5 (28) 1 (33) 1 (20) 20 (35)
Non-evaluablea 2 (40) 2 (40) 1 (33) 2 (33) 1 (11) 0 4 (22) 0 0 12 (21)
  1. Abbreviations: CR complete response, PD progressive disease, PR partial response, SD stable disease
  2. aIncludes patients who discontinued study before first disease assessment and patients for whom not all target lesions were evaluated
  3. bKidney cancer
  4. cMelanoma
  5. dKidney cancer (n = 1), melanoma with BRAF mutation (n = 1)
  6. eMelanoma with BRAF mutation